Author: Bella Hayes

By Phil Stewart and Oliver Griffin WASHINGTON/BOGOTA (Reuters) -President Donald Trump said on Sunday he will impose sweeping retaliatory measures on Colombia, including tariffs and sanctions, after the South American country turned away two U.S. military aircraft with migrants being deported as part of the new U.S. administration’s immigration crackdown. Colombia, America’s third largest trading partner in Latin America, swifly responded, threatening a 50% tariff on U.S. goods. Trump’s punitive action appeared aimed at making an example of Colombia, the second case of a Latin American nation refusing U.S. military deportation flights. It was a demonstration of a more muscular…

VANCOUVER, British Columbia, Jan. 26, 2025 (GLOBE NEWSWIRE) — Orezone Corporation (TSX: ORE, OTCQX: ORZCF) (the Company or Orezone) is pleased to provide additional drill results from its recently announced multi-year exploration campaign at its flagship Bomboré Gold Mine. The new results are centered on the North Zone, with high grades intercepted below both the North Zone Footwall and North Zone Hill resource and reserve pits. Selected Drill Highlights: 2.55 g/t Au over 23.00m, including 5.54 g/t Au over 5.00m (BBD1324)1.14 g/t Au over 29.50m, including 2.30 g/t Au over 4.50m (BBD1320) 1.20 g/t Au over 23.80m (BBD1323)1.01 g/t Au…

New York, New York–(Newsfile Corp. – January 26, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Dave Inc. (NASDAQ: DAVE) resulting from allegations that Dave may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Dave securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the…

New York, New York–(Newsfile Corp. – January 26, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Nextracker Inc. (NASDAQ: NXT) between February 1, 2024 and August 1, 2024, both dates inclusive (the “Class Period”), of the important February 25, 2025 lead plaintiff deadline. SO WHAT: If you purchased Nextracker common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Nextracker class action, go to https://rosenlegal.com/submit-form/?case_id=32936 or…

New York, New York–(Newsfile Corp. – January 26, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron (NASDAQ:) Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), of the important March 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Regeneron class action, go to https://rosenlegal.com/submit-form/?case_id=33630 or…

New York, New York–(Newsfile Corp. – January 26, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of common stock of Crocs , Inc. (NASDAQ: NASDAQ:) between November 3, 2022 and October 28, 2024, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 24, 2025. SO WHAT: If you purchased Crocs common stock during the Class Period you may be entitled to compensation without…

Stock Story – Measurement equipment distributor Transcat (NASDAQ:) will be reporting earnings tomorrow afternoon. Here’s what to look for. Transcat missed analysts’ revenue expectations by 3.5% last quarter, reporting revenues of $67.83 million, up 8% year on year. It was a disappointing quarter for the company, with a significant miss of analysts’ EBITDA and EPS estimates. Is Transcat a buy or sell going into earnings? Find out by reading the original article on StockStory, it’s free. This quarter, analysts are expecting Transcat’s revenue to grow 7.9% year on year to $70.3 million, slowing from the 13.5% increase it recorded in…

U.Today – It’s not every day that the CEO of a major cryptocurrency exchange and a vocal critic find themselves in a back-and-forth, but here we are. Brian Armstrong, the head of Coinbase (NASDAQ:), recently pointed out a problem that’s both a blessing and a curse for the crypto industry: the sheer volume of new tokens being created. With around 1 million tokens popping up every week, Armstrong argued that the current system of evaluating each one individually is no longer feasible. Instead, he suggested a shift from an “allow list” to a “block list,” relying on customer reviews and…

New York, New York–(Newsfile Corp. – January 26, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities, including call options, of Five9, Inc. (NASDAQ: NASDAQ:) between June 4, 2024 and August 8, 2024, both dates inclusive (the “Class Period”), of the important February 3, 2025 lead plaintiff deadline. SO WHAT: If you purchased Five9 securities or call options during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Five9 class action,…

GOLETA, Calif.–(BUSINESS WIRE)–Inogen, Inc. (: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has entered into a strategic collaboration with Jiangsu Yuyue Medical (TASE:) Equipment & Supply Co., Ltd. (002223.SZ, Yuwell), a global home healthcare medical device manufacturer with a comprehensive portfolio of respiratory products. The strategic collaboration is expected to broaden Inogen (NASDAQ:)’s product portfolio through distribution of certain respiratory products in the United States and select other territories, expand and enhance Inogen’s innovation pipeline through R&D collaboration, and accelerate the entry of Inogen’s brand into the Chinese market.…